Investment Rating - The report initiates coverage with a "Buy" rating for the company, indicating a positive outlook for the stock price over the next six months [6]. Core Insights - The company reported a revenue of 734 million in 2024, representing a 32% increase year-on-year. The gross profit was 404 million, up 28.4%, while the net profit attributable to shareholders was a loss of 138 million, a decrease of 8.5% [1]. - The G-end business remains stable, while the B/C-end business shows significant growth. The loss situation is continuously improving, with adjusted net profit margin at -6.1%, an increase of 4.1 percentage points [1]. - The company has made substantial advancements in AI medical technology, with the Starfire Medical Model 2.0 achieving an average effectiveness improvement to 88% across six core scenarios [2]. - The customer base has expanded significantly, with the AI assistant covering over 30 provinces and 67,000 grassroots medical institutions, providing 910 million AI-assisted diagnosis suggestions [3]. Financial Summary - For 2025, the company is projected to achieve revenues of 926 million, with a net loss of 83.4 million. The earnings per share are expected to improve from -1.16 in 2024 to -0.69 in 2025 [5][12]. - The gross margin is expected to remain stable at around 55.1% in 2024, with a gradual improvement forecasted in subsequent years [13]. - The company’s total assets are projected to grow from 2,090 million in 2024 to 3,599 million by 2027, indicating a strong growth trajectory [13].
讯飞医疗科技（02506）：2024年度业绩点评：引领AI医疗，G端业务稳健，B/C端业务高增